Overview Dividends

(PODD) Insulet - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45784P1012

Insulin Pump, Automated Delivery, Wireless Pods, Drug Device

Health Care Equipment
Market Cap in USD: 20,384m
IPO / Inception: 2007-05-15
Return 12m vs S&P 500: -6.41%

EPS (Earnings per Share)

EPS (Earnings per Share) of PODD over the last years for every Quarter: "2020-12": -0.04, "2021-03": 0, "2021-06": 0.23, "2021-09": 0.18, "2021-12": 0.42, "2022-03": 0.4, "2022-06": -0.5, "2022-09": 0.35, "2022-12": 0.24, "2023-03": 0.23, "2023-06": 0.38, "2023-09": 0.71, "2023-12": 1.4, "2024-03": 0.73, "2024-06": 0.55, "2024-09": 0.9, "2024-12": 1.15, "2025-03": 1.02, "2025-06": 1.17, "2025-09": 1.24,
EPS CAGR: 33.47%
EPS Trend: 76.5%
Last SUE: 0.45
Qual. Beats: 0

Revenue

Revenue of PODD over the last years for every Quarter: 2020-12: 246.1, 2021-03: 252.3, 2021-06: 263.2, 2021-09: 275.6, 2021-12: 307.7, 2022-03: 295.4, 2022-06: 299.4, 2022-09: 340.8, 2022-12: 369.7, 2023-03: 358.1, 2023-06: 396.5, 2023-09: 432.7, 2023-12: 509.8, 2024-03: 441.7, 2024-06: 488.5, 2024-09: 543.9, 2024-12: 597.5, 2025-03: 569, 2025-06: 649.1, 2025-09: 706.3,
Rev. CAGR: 24.80%
Rev. Trend: 98.1%
Last SUE: 2.47
Qual. Beats: 16

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 38.5%
Value at Risk 5%th 57.3%
Relative Tail Risk -9.53%
Reward TTM
Sharpe Ratio 0.32
Alpha -7.11
CAGR/Max DD -0.01
Character TTM
Hurst Exponent 0.594
Beta 0.806
Beta Downside 1.196
Drawdowns 3y
Max DD 61.31%
Mean DD 24.28%
Median DD 19.69%

Description: PODD Insulet December 19, 2025

Insulet Corporation (NASDAQ:PODD) designs, manufactures, and markets tubeless insulin-delivery systems for people with insulin-dependent diabetes, primarily through its Omnipod platform. The Omnipod 5 combines a proprietary automated insulin-delivery (AID) algorithm with Bluetooth-linked continuous glucose monitoring, while the Omnipod DASH uses a smartphone-style personal diabetes manager to control a Bluetooth-enabled pod. Insulet also supplies pods to Amgen for the Neulasta Onpro chemotherapy kit and distributes its products via pharmacies and independent distributors.

Key recent metrics: FY 2023 revenue reached roughly $2.5 billion, up about 16 % YoY, driven by a ~30 % market-share position in the U.S. tubeless pump segment and expanding adoption of automated insulin delivery. Gross margins have remained high at ~70 %, reflecting the premium nature of the hardware and software bundle, while R&D spending stays near 10 % of revenue to sustain algorithm improvements. A macro driver is the continued rise in diabetes prevalence-over 10 % of U.S. adults-supporting long-term demand for advanced insulin-delivery solutions.

For a deeper quantitative assessment, you may find ValueRay’s platform useful for drilling into Insulet’s valuation metrics and peer comparisons.

Piotroski VR‑10 (Strict, 0-10) 9.0

Net Income (246.2m TTM) > 0 and > 6% of Revenue (6% = 151.3m TTM)
FCFTA 0.14 (>2.0%) and ΔFCFTA 5.74pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 48.05% (prev 67.31%; Δ -19.26pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.18 (>3.0%) and CFO 533.7m > Net Income 246.2m (YES >=105%, WARN >=100%)
Net Debt (273.9m) to EBITDA (451.2m) ratio: 0.61 <= 3.0 (WARN <= 3.5)
Current Ratio 2.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (70.7m) change vs 12m ago -4.45% (target <= -2.0% for YES)
Gross Margin 71.46% (prev 69.36%; Δ 2.10pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 83.30% (prev 65.57%; Δ 17.73pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 6.85 (EBITDA TTM 451.2m / Interest Expense TTM 53.1m) >= 6 (WARN >= 3)

Altman Z'' 3.76

(A) 0.40 = (Total Current Assets 1.86b - Total Current Liabilities 647.7m) / Total Assets 3.03b
(B) 0.06 = Retained Earnings (Balance) 185.8m / Total Assets 3.03b
(C) 0.12 = EBIT TTM 363.7m / Avg Total Assets 3.03b
(D) 0.12 = Book Value of Equity 199.0m / Total Liabilities 1.65b
Total Rating: 3.76 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 77.50

1. Piotroski 9.0pt
2. FCF Yield 2.04%
3. FCF Margin 16.70%
4. Debt/Equity 0.75
5. Debt/Ebitda 0.61
6. ROIC - WACC (= 0.92)%
7. RoE 18.27%
8. Rev. Trend 98.10%
9. EPS Trend 76.49%

What is the price of PODD shares?

As of December 26, 2025, the stock is trading at USD 288.82 with a total of 294,258 shares traded.
Over the past week, the price has changed by -1.39%, over one month by -12.17%, over three months by -10.74% and over the past year by +8.71%.

Is PODD a buy, sell or hold?

Insulet has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy PODD.
  • Strong Buy: 14
  • Buy: 6
  • Hold: 2
  • Sell: 1
  • Strong Sell: 0

What are the forecasts/targets for the PODD price?

Issuer Target Up/Down from current
Wallstreet Target Price 378.6 31.1%
Analysts Target Price 378.6 31.1%
ValueRay Target Price 292.2 1.2%

PODD Fundamental Data Overview December 19, 2025

Market Cap USD = 20.38b (20.38b USD * 1.0 USD.USD)
P/E Trailing = 84.1773
P/E Forward = 46.5116
P/S = 8.0829
P/B = 14.6665
P/EG = 2.1516
Beta = 1.375
Revenue TTM = 2.52b USD
EBIT TTM = 363.7m USD
EBITDA TTM = 451.2m USD
Long Term Debt = 934.9m USD (from longTermDebt, last quarter)
Short Term Debt = 96.4m USD (from shortTermDebt, last quarter)
Debt = 1.03b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 273.9m USD (from netDebt column, last quarter)
Enterprise Value = 20.66b USD (20.38b + Debt 1.03b - CCE 757.4m)
Interest Coverage Ratio = 6.85 (Ebit TTM 363.7m / Interest Expense TTM 53.1m)
FCF Yield = 2.04% (FCF TTM 421.2m / Enterprise Value 20.66b)
FCF Margin = 16.70% (FCF TTM 421.2m / Revenue TTM 2.52b)
Net Margin = 9.76% (Net Income TTM 246.2m / Revenue TTM 2.52b)
Gross Margin = 71.46% ((Revenue TTM 2.52b - Cost of Revenue TTM 719.7m) / Revenue TTM)
Gross Margin QoQ = 72.22% (prev 69.67%)
Tobins Q-Ratio = 6.82 (Enterprise Value 20.66b / Total Assets 3.03b)
Interest Expense / Debt = 1.51% (Interest Expense 15.6m / Debt 1.03b)
Taxrate = 28.66% (35.2m / 122.8m)
NOPAT = 259.4m (EBIT 363.7m * (1 - 28.66%))
Current Ratio = 2.87 (Total Current Assets 1.86b / Total Current Liabilities 647.7m)
Debt / Equity = 0.75 (Debt 1.03b / totalStockholderEquity, last quarter 1.38b)
Debt / EBITDA = 0.61 (Net Debt 273.9m / EBITDA 451.2m)
Debt / FCF = 0.65 (Net Debt 273.9m / FCF TTM 421.2m)
Total Stockholder Equity = 1.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.13% (Net Income 246.2m / Total Assets 3.03b)
RoE = 18.27% (Net Income TTM 246.2m / Total Stockholder Equity 1.35b)
RoCE = 15.94% (EBIT 363.7m / Capital Employed (Equity 1.35b + L.T.Debt 934.9m))
RoIC = 9.53% (NOPAT 259.4m / Invested Capital 2.72b)
WACC = 8.61% (E(20.38b)/V(21.41b) * Re(8.99%) + D(1.03b)/V(21.41b) * Rd(1.51%) * (1-Tc(0.29)))
Discount Rate = 8.99% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.57%
[DCF Debug] Terminal Value 66.29% ; FCFE base≈351.5m ; Y1≈230.8m ; Y5≈105.5m
Fair Price DCF = 25.30 (DCF Value 1.78b / Shares Outstanding 70.3m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 76.49 | EPS CAGR: 33.47% | SUE: 0.45 | # QB: 0
Revenue Correlation: 98.10 | Revenue CAGR: 24.80% | SUE: 2.47 | # QB: 16
EPS next Quarter (2026-03-31): EPS=1.19 | Chg30d=-0.000 | Revisions Net=+6 | Analysts=18
EPS next Year (2026-12-31): EPS=6.18 | Chg30d=+0.094 | Revisions Net=+22 | Growth EPS=+26.5% | Growth Revenue=+20.6%

Additional Sources for PODD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle